William Blair & Company
TLX

William Blair & Company’s Telix Pharmaceuticals TLX Stock Holding History

William Blair & Company’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,500
Closed -$217K – 1919
2025
Q2 		$217K Buy
+13,500
New +$227K ﹤0.01% 1390

Other funds holding TLX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

William Blair & Company's TLX Position: Q3 2025 in Review

William Blair & Company sold out of Telix Pharmaceuticals (TLX) in Q3 2025, closing a stake of 13,500 shares — an estimated $217K sold.

William Blair & Company first reported a position in TLX in Q2 2025 and held it in 1 quarter. The position peaked at $217K in Q2 2025. 27 funds tracked by Wall St. Rank hold TLX as of Q3 2025.

  • William Blair & Company reported no remaining Telix Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • William Blair & Company sold 13,500 Telix Pharmaceuticals shares in Q3 2025, an estimated $217K.
  • William Blair & Company first reported a position in Telix Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • William Blair & Company's Telix Pharmaceuticals position peaked at $217K in Q2 2025.
  • 27 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2025.

Based on William Blair & Company's 13F filing for Q3 2025, filed 12 Nov 2025.